All Pharma News
What Makes Immunovant (IMVT) a New Buy Stock

What Makes Immunovant (IMVT) a New Buy Stock
YAHOO FINANCE
17 Apr 2024
Share Share
Immunovant Awarded U.S. Patent for IMVT-1402

Immunovant Awarded U.S. Patent for IMVT-1402
GLOBENEWSWIRE
12 Mar 2024
Share Share
Immunovant Reports Financial Results

Immunovant Reports Financial Results
GLOBENEWSWIRE
12 Feb 2024
Share Share
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GLOBENEWSWIRE
03 Jan 2024
Share Share
Immunovant unveils positive early data for PhII Graves` disease drug

Immunovant unveils positive early data for PhII Graves` disease drug
ENDPTS
21 Dec 2023
Share Share
Immunovant posts midphase FcRn data in Graves’, plots next steps

Immunovant posts midphase FcRn data in Graves’, plots next steps
Nick Paul Taylor FIERCE BIOTECH
21 Dec 2023
Share Share
Immunovant Reports Positive Phase 2 Results for Batoclimab in Graves™ Disease

Immunovant Reports Positive Phase 2 Results for Batoclimab in Graves™ Disease
GLOBENEWSWIRE
20 Dec 2023
Share Share
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results
GLOBENEWSWIRE
28 Nov 2023
Share Share
Immunovant to Present at Upcoming Investor Conferences

Immunovant to Present at Upcoming Investor Conferences
GLOBENEWSWIRE
13 Nov 2023
Share Share
Immunovant Reports Financial Results for the Quarter Ended September 30, 2023

Immunovant Reports Financial Results for the Quarter Ended September 30, 2023
GLOBENEWSWIRE
09 Nov 2023
Share Share